The DePuy Attune knee replacement failure class action involves lawsuits against Johnson & Johnson and its DePuy subsidiary over a defective knee implant that has failed in thousands of patients since 2017. The primary issue is tibial loosening—the implant’s base plate is failing to properly bond to the patient’s tibia (lower leg bone) because the cement cannot adhere to the device’s surface. This design flaw has prompted individual lawsuits across the country, though the class action was ordered to discontinue, leaving patients to pursue claims individually.
The DePuy Attune knee has been implanted in more than 400,000 procedures since the FDA approved it in 2010, making it one of the more widely distributed knee replacement devices in the market. While the FDA has never issued a recall for the Attune, the failure rate has sparked significant litigation. As of now, one mass litigation case is underway in federal court in the settlement phase, though no large group settlements have been reached yet. This stands in contrast to J&J’s earlier settlement of ASR hip replacement lawsuits for $2.5 billion in 2013, which resolved approximately 8,000 claims—a sobering reminder of what defective implant litigation can cost manufacturers.
Table of Contents
- WHAT IS TIBIAL LOOSENING IN THE DEPUY ATTUNE KNEE?
- THE DESIGN DEFECT EXPLAINED
- LITIGATION TIMELINE AND CURRENT STATUS
- WHO IS AFFECTED AND FILING A CLAIM
- SYMPTOMS AND WARNING SIGNS OF IMPLANT FAILURE
- SETTLEMENT OUTLOOK AND COMPENSATION EXPECTATIONS
- WHAT THE FUTURE HOLDS FOR DEPUY ATTUNE LITIGATION
- Conclusion
WHAT IS TIBIAL LOOSENING IN THE DEPUY ATTUNE KNEE?
Tibial loosening is the primary failure mechanism affecting DePuy Attune knee replacements. The implant consists of a metal base plate designed to fuse permanently to the patient’s tibia using bone cement. When tibial loosening occurs, this cement bond fails, causing the implant to shift, rock, or separate from the bone. Patients experience pain, instability, reduced range of motion, and eventually the implant may require revision surgery to replace it. The root cause of this failure is a design choice that has become the central point of litigation: the DePuy Attune knee is manufactured 75% smoother than previous generation knee replacement prosthetics. While a smoother surface might seem beneficial for reducing wear, the increased smoothness prevents the bone cement from creating a durable mechanical bond.
The cement cannot grip the polished surface adequately, leading to failure over time. This is a critical design flaw because patients typically undergo knee replacement expecting the device to last 15-20 years or longer—not to fail within the first few years. Consider a patient who underwent Attune implantation in 2015. By 2019, they might begin experiencing unexplained knee pain during basic activities like climbing stairs. Within months, imaging reveals the implant has loosened. Now that patient faces revision surgery—a more complex and risky procedure than the original replacement—and the resulting scar tissue and bone loss from the failed implant make successful revision more difficult.
THE DESIGN DEFECT EXPLAINED
The smoothness of the depuy Attune knee component is not accidental—it appears to have been a deliberate engineering choice. In traditional knee implants, the surface texture allows bone cement to interlock with the base plate, creating a mechanical grip that holds the implant in place. DePuy’s decision to make the Attune 75% smoother represents a significant departure from this proven design principle, and this change was apparently made without adequate testing to ensure the cement would still achieve proper bonding under the mechanical stresses patients experience during normal activity. This design decision reflects a critical limitation of the approval process: the FDA’s 510(k) pathway allows manufacturers to bring devices to market based on “substantial equivalence” to predicate devices, even when significant design changes are made.
The Attune’s smoothness was not the same as its predicates, yet it still received approval. Engineers and surgeons have since questioned whether DePuy adequately validated that cementing procedures would work on such a smooth surface, or whether the company prioritized other design goals—such as aesthetics or manufacturing efficiency—without fully considering the cement bonding implications. A major warning for patients: many who had Attune implants are unaware of this defect and may not associate early symptoms with implant failure. Subtle pain, a feeling of the knee “giving way,” or difficulty with certain movements might be attributed to normal post-operative issues rather than recognized as signs of loosening. By the time loosening is confirmed on imaging, significant damage may have already occurred.
LITIGATION TIMELINE AND CURRENT STATUS
The first lawsuits against DePuy regarding the Attune knee were filed in 2017, approximately seven years after the device’s FDA approval. These early cases alleged that the company knew or should have known about the tibial loosening problem but failed to warn patients and surgeons adequately. As more lawsuits accumulated, the case met the threshold for federal multi-district litigation (MDL), which consolidates similar cases for more efficient handling. A class action order to discontinue was issued, which meant that instead of a single class-wide settlement benefiting all affected patients, individual lawsuits are proceeding separately. However, one mass litigation case is currently underway in federal court and has entered the settlement phase.
This means lawyers are actively negotiating with DePuy to reach a settlement framework, though no final agreement has been announced. The slow pace of these settlements reflects both the complexity of proving the defect and the company’s apparent reluctance to admit wrongdoing—a typical pattern in device litigation where manufacturers settle without acknowledging the product was defective. The contrast with DePuy’s history is notable. When the ASR hip replacement—another problematic DePuy implant—faced similar litigation, J&J eventually settled for $2.5 billion to resolve approximately 8,000 claims. That settlement came after years of litigation and numerous failed implants reported. The Attune litigation is now on a similar trajectory, but it remains to be seen whether a settlement of comparable magnitude will ultimately result.
WHO IS AFFECTED AND FILING A CLAIM
Patients who received a DePuy Attune knee replacement and subsequently experienced failure, revision surgery, or significant complications may be eligible to pursue a claim. This includes individuals who had the device implanted at any point since its 2010 FDA approval, though most identified cases involve implants from approximately 2015 onward, when the failure pattern began to emerge in clinical practice. To file a claim, patients typically need to document: the date of implantation, medical records confirming implant failure or loosening, evidence of revision surgery or ongoing complications, and documentation of associated medical expenses and pain. A key comparison: unlike some product liability cases where plaintiffs must prove the manufacturer deliberately concealed defects, implant cases often proceed on design defect theories, which only require showing the product was unreasonably dangerous due to its design—even if unintentional.
A critical limitation to understand is timing. Most states have statutes of limitation that cap how long after implant failure you can file a lawsuit. For some patients, especially those who experienced failure years after implantation, the window for action may be closing. Any patient who believes they have a problematic Attune implant should consult with an attorney specializing in device litigation as soon as possible.
SYMPTOMS AND WARNING SIGNS OF IMPLANT FAILURE
Patients with a loosening or failing DePuy Attune knee may experience a range of symptoms, though the severity and timeline vary considerably. Common warning signs include persistent pain not relieved by physical therapy, a sensation that the knee is unstable or “giving way,” swelling that appears or worsens suddenly, difficulty walking without assistance, and a clicking, grinding, or popping sensation. Some patients describe the sensation as the knee not “tracking” properly during movement. A warning: early symptoms can be subtle and easily dismissed as normal post-operative pain or simply aging. One patient reported mild discomfort during stair climbing three years after implantation, which their surgeon attributed to muscle weakness.
Within six months, the pain became severe and imaging revealed significant loosening. By that point, the longer duration of the loose implant had caused additional bone damage, making revision surgery more complicated. Early imaging—X-rays or CT scans—can identify loosening before symptoms become severe, so patients should not ignore persistent symptoms or dismiss them without definitive imaging. The timeline of failure is unpredictable. Some patients experience symptoms within a few years of implantation, while others may go five or more years before problems emerge. This variability makes it difficult to predict how many additional failures might occur in coming years among the 400,000 patients who received the device.
SETTLEMENT OUTLOOK AND COMPENSATION EXPECTATIONS
As of now, no large group settlement has been finalized for the DePuy Attune knee implant. However, the ongoing mass litigation in federal court is in active settlement discussions. If a settlement is reached, patients may expect compensation for medical expenses (surgeon fees, hospital costs, revision surgery), lost wages during recovery and time off work, pain and suffering, and in some cases, punitive damages if the defendant’s conduct was deemed particularly egregious.
An example from comparable implant settlements: the ASR hip settlement provided compensation ranging from tens of thousands to several hundred thousand dollars per claimant, depending on the extent of injury and documented complications. It’s reasonable to expect that Attune settlements, if finalized, could follow a similar framework, though the actual amounts would depend on the specific severity of each patient’s case, the quality of evidence, and the negotiating power of the legal teams involved. A limitation to understand: settlement negotiations often result in lower per-claimant payouts than some patients hope for, especially if the number of eligible claimants is very large.
WHAT THE FUTURE HOLDS FOR DEPUY ATTUNE LITIGATION
The Attune knee litigation is likely to continue expanding for several more years as additional patients experience failure and join existing lawsuits. The lack of an FDA recall, combined with the device’s continued use in procedures, means that new failure cases will likely emerge even as existing litigation progresses. Surgeons and patients now have much better information about the Attune’s limitations, and implant selection has shifted toward alternative knee replacement systems with proven track records.
Looking forward, this litigation serves as a cautionary tale about the importance of long-term device monitoring and the limitations of relying solely on FDA approval as a guarantee of safety. While the Attune was approved through a standard regulatory pathway, the real-world performance data has revealed a design flaw that approval processes did not catch. Future regulations may require more rigorous testing of surface modifications and cement bonding in knee implants, and manufacturers may face stricter post-market surveillance requirements to identify problems earlier.
Conclusion
The DePuy Attune knee replacement failure class action represents a significant product liability case involving a widely distributed medical device that has caused substantial harm to thousands of patients. The core issue—tibial loosening caused by the implant’s design—is well-documented, the litigation timeline is clear, and one major settlement case is actively underway.
While no large group settlement has been reached yet, the precedent of J&J’s $2.5 billion ASR hip settlement suggests that eventual resolution of Attune claims is likely, though the timeline remains uncertain. If you or a family member received a DePuy Attune knee replacement and have experienced pain, instability, or complications suggesting implant failure, contacting an attorney who specializes in medical device litigation is the appropriate next step. Time is critical due to statute of limitations constraints, and early documentation of symptoms and medical records can strengthen your claim significantly.